Document is current
Any future updates will be listed below
-
Authors
Salomon, Ran http://orcid.org/0000-0002-8197-3052
Rotem, Hagar
Katzenelenbogen, Yonatan
Weiner, Assaf http://orcid.org/0000-0002-5389-9668
Cohen Saban, Noy http://orcid.org/0000-0002-8683-2152
Feferman, Tali
Amit, Ido http://orcid.org/0000-0003-2968-877X
Dahan, Rony http://orcid.org/0000-0002-8420-7601
-
Funding
Funding for this research was provided by:
Israel Cancer Research Fund (na)
- License Information
-
More Information
Article History
Received: 8 March 2021
Accepted: 4 January 2022
First Online: 21 February 2022
Competing interests
: The Weizmann Institute has filed a PCT patent application (no. WO2021/149053) related to this work, on which R.S. and R.D. are inventors. The patent application has been licensed to Teva Pharmaceuticals Industries Ltd. R.D. serves as a consultant for Teva Pharmaceuticals Industries Ltd and NucleAi Ltd, and receives research grant support from Teva Pharmaceuticals Industries Ltd. The remaining authors declare no competing interests.
